Good DD on (NASDAQ: CLRX) Large merger LOI Update

New Post Public Reply Private Reply Replies (0) Message Board
SmallCapTraders
Good DD on (NASDAQ: CLRX) Large merger LOI

Update CollabRX, Inc. (NASDAQ: CLRX) in our opinion has a whole lot to gain with the acquisition/merger of Medytox (OTCQB: MMMS) here’s why.

Medytox total shareholders’ equity of $38M vs. CollabRX at $3.6M (Remember the NASDAQ letter was due to shareholders equity in CLRX dropping below 2.5M)

Medytox revenue (NET) $18.2M for the 3 months ending September 30th , 2014 vs. CollabRX $158K

Medytox (Gross) Revenue $22.8M for the 3 months ending September 30th, 2014 vs. CollabRX 176K

Taglich Brothers recently issued a $7.00/share price target for CLRX and then downgraded still with a “buy” to $2.00/share based on financing arrangements and potential dilution this summer. This came in before the announcement of the LOI for merger with MMMS. In our opinion in light of this new information we could see a target much, much higher than the original.



The Team

original report

You asked for an exciting play with potential for BIG near term gains and we plan to deliver today! Let’s get right to it.

CollabRX, Inc. (NASDAQ: CLRX) named one of the top four NASDAQ stocks In the Healthcare Information Services Industry with the Highest EPS Growth Forecast for Next Year by Benzinga.com. Benzinga full report: http://www.benzinga.com/trading-ideas/15/01/5...ustry-with

The most recent price of CollabRx Inc (NASDAQ:CLRX) is now at a discount of -72.89% to the 12-month high of $4.02 hit on Jan 14, 2014.

CollabRx, Inc. (NASDAQ: CLRX) earnings per share growth forecast for the next year is 62.30%. CollabRx's trailing-twelve-month gross margin is 50%.


Recent LOI for Merger with Medytox announced on January 22nd, 2015

LOI for merger with Medytox, here is a quote directly from an 8-K filing on January 16th, 2015 and part of the reason we believe that this merger will happen.

“Pursuant to the Letter of Intent, Medytox has agreed to advance certain funding to CollabRx in contemplation of the business combination. On January 16, 2015, CollabRx entered into a Loan and Security Agreement (the “Loan Agreement”) with Medytox, pursuant to which it is contemplated that Medytox will loan up to $2,395,644 to the Company. Medytox is a holding company that owns and operates businesses in the medical services sector. Its principal line of business is clinical laboratory blood and urine testing services, with a particular emphasis in the provision of urine drug toxicology and comprehensive pain medication monitoring programs to physicians, clinics and rehabilitation facilities in the United States.”

Link to full 8-K filing: http://www.otcmarkets.com/edgar/GetFilingHtml...D=10420489

We might also note a slew of Form 4’s filed dating back to December12th, 2014 showing insider buy’s in CLRX stock.

Let’s talk about the elephant in the room. The risk and warnings from NASDAQ recently in regards to listing requirements.

SAN FRANCISCO, Dec. 3, 2014 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX) (herein "CLRX" or "the Company" , announced today that it received a letter from the NASDAQ OMX GROUP ("Nasdaq" stating that the Company is in non-compliance with the Nasdaq Capital Market's Listing Rule 5550(b)(1). That rule requires the Company to maintain a minimum stockholder's equity of $2,500,000 for continued listing.

The Company has 45 days to prepare and submit a plan to Nasdaq to regain compliance. If the plan is accepted, Nasdaq may grant the Company an extension of up to 180 days from November 20, 2014 to evidence compliance. This announcement is being made in compliance with Listing Rule 5810(b), which requires prompt disclosure of receipt of a noncompliance letter. The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted on the Nasdaq Capital Market under the symbol "CLRX."

CollabRx management intends to resolve the situation to allow for continued listing on the Nasdaq Capital Market.

Full PR: http:// http://globenewswire.com/news-release/2014/12...0-b-1.html

SAN FRANCISCO, Jan 20, 2015 (GLOBE NEWSWIRE via COMTEX) -- CollabRx, Inc. (Nasdaq:CLRX) ("the Company" announced that it received a letter from the NASDAQ Listing Qualifications Staff indicating that, unless the Company timely requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel" , the Company's securities would be delisted from The NASDAQ Capital Market due to the Company's non-compliance with NASDAQ Listing Rule 5550(b)(1) (the "Rule" . The Company intends to timely request a hearing before the Panel, at which hearing the Company will present its plan to evidence compliance with the Rule, which requires the Company to maintain a minimum of $2.5 million in stockholders' equity. The Company's common stock will continue to trade on The NASDAQ Capital Market under the symbol "CLRX" pending completion of the hearing process and the expiration of any extension period granted by the Panel.

Full PR: http://globenewswire.com/news-release/2015/01...aring.html

So, as you can see this delisting notice does not appear to be an immediate threat to the securities and has very good odds of being resolved prior to the May 2015 deadline. Furthermore, there is no doubt that this has contributed to the decline in the securities.

Updated report in regards to the potential merger entity Medytox coming soon.

The Team

“Small-cap stocks are like a deserted lagoon lately. Too insignificant to have drawn Wall Street’s attention, many small companies are pearls of potential profit, waiting for the right catalyst to value them into the limelight. Although there’s plenty of risk involved, the rewards can be nearly limitless.”






Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 20

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 79

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Venezuela's Political Shift and Its Impact on Global Oil Markets

Updated Category News Views 122

Venezuela's Dramatic Political Changes and Market Reactions Recent events in Venezuela have created quite a stir. With the U.S. capturing Nicolás Maduro, the country's president, and extraditing him for trial, one might expect a major upheaval in financial and commodity markets. Surprisingly, the markets seem largely unaffected by this significant geopolitical shift....

Continue Reading
Paradigm Health Pushes Innovative FDA Trial Initiative

Updated Category News Views 27

The FDA's Real-Time Game Changer Just up and submitting their convincing response to the FDA, Paradigm Health's grabbing headlines with a trailblazing initiative right out of Columbus, Ohio. The FDA's Real-Time Clinical Trials (RTCT) proof-of-concept has been a field where Paradigm wields its AI-driven wand, proposing a plan that promises to streamline clinical trial...

Continue Reading
DSV A/S Launches Major Share Buyback Program Announcement

Updated Category News Views 74

DSV A/S Launches Major Share Buyback Program Company Announcement No. 1130 In a strategic effort to boost shareholder value, DSV A/S has launched a share buyback program. This initiative officially began on July 24, 2024, and is expected to wrap up on October 22, 2024. The company plans to repurchase its own shares totaling up to DKK 1,500 million, which corresponds to a...

Continue Reading
Insights into the Growth of the Global Fondant Market Trends

Updated Category News Views 230

Exploring the Global Fondant Market Trends The fondant market is rapidly evolving, driven by a surge in consumer preferences for aesthetically pleasing dessert options. Recent research identifies that the fondant market size, valued at approximately USD 520.45 Million, is anticipated to reach around USD 898.79 Million by 2034, reflecting a robust compound annual growth...

Continue Reading
Innocan Pharma's Strategic Move: Private Placement Details

Updated Category News Views 110

Innocan Pharma's Exciting Private Placement Initiative Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a significant financial move by planning a non-brokered private placement. This initiative aims to issue up to 3,500,000 units, priced at C$0.20 each, bringing in gross proceeds of up to C$700,000. This offering is designed to expedite the...

Continue Reading